Compare Amphastar Pharmaceuticals Inc (AMPH) vs KLA Corp. (KLAC) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

KLA Corporation (KLAC) trades at $231.52, up 0.88% on the day, with a neutral technical signal and bullish moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.94 exceeding the $0.917 estimate. Revenue grew to $12.16 billion in 2025, driving a net income margin of 35.66%. A 1:10 stock split is scheduled for June 12, 2026, and a $2.30 dividend was paid in June 2026.

KLAC's outlook is supported by AI-driven semiconductor equipment demand and consistent earnings outperformance, but high valuation ratios (P/E 65.57, P/S 23.38) pose risks if growth slows. Analysts maintain a buy consensus with a $239.86 price target, though competitive pressures and market volatility remain concerns for shareholders.